普拉克索联合多巴丝肼片治疗帕金森病的效果

Effect of Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of Parkinson's disease

目的分析研究普拉克索结合多巴丝肼片用于帕金森病治疗中的价值。方法选取2020年1月至2023年1月湖北省麻城市人民医院神经内科首次确诊为帕金森病的50例患者作为研究对象,按照随机数字表法分为两组,每组25例。观察组给予普拉克索联合多巴丝肼片治疗,对照组仅给予多巴丝肼片治疗。两组均指标3个月,对比两组患者的临床疗效、运动症状、生活质量、同型半胱氨酸(Hcy)、β淀粉样蛋白1-42(Aβ1-42)水平,以及用药安全性。结果观察组临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组治疗前统一帕金森病综合评分量表(UPDRS)Ⅱ、UPDRSⅢ、UPDRSⅡ+Ⅲ评分比较,差异无统计学意义(P>0.05);观察组UPDRSⅡ、UPDRSⅢ、UPDRSⅡ+Ⅲ治疗后评分低于对照组,差异有统计学意义(P<0.05)。两组治疗前帕金森病生活质量量表(PDQ-39)评分比较,差异无统计学意义(P>0.05);观察组治疗后PDQ-39评分低于对照组,差异有统计学意义(P<0.05)。两组治疗前血清Hcy、Aβ1-42比较,差异无统计学意义(P>0.05);观察组治疗后血清Hcy低于对照组,Aβ1-42水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论普拉克索+多巴丝肼片用于帕金森病治疗中单纯多巴丝肼片使用价值明显更好,同时可明显改善患者运动症状,提升生活质量和Aβl-42水平,降低Hcy水平,且安全性较高,值得临床广泛应用。

Objective To analyze and study the value of Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of Parkinson's disease.Methods Fifty patients diagnosed with Parkinson's disease for the first time in the Department of Neurology,Macheng City People's Hospital,Hubei Province from January 2020 to January 2023 were selected as the observation subjects of this study.All patients were divided into two groups using random number table method,with 25 cases in each group.The observation group was treated with Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets,while the control group was only treated with Levodopa and Benserazide Hydrochloride Tablets.Both groups were treated for 3 months.Clinical efficacy,movement symptoms,quality of life,homocysteine(Hcy),amyloid-βprotein 1-42(Aβ1-42)levels,and drug safety were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There were no statistically significant difference in Parkinson's disease rating scale(UPDRS)Ⅱ,UPDRSⅢ,UPDRSⅡ+Ⅲscore between the two groups before treatment(P>0.05).The UPDRSⅡ,UPDRSⅢand UPDRSⅡ+Ⅲscores of the observation group were lower than those of the control group after treatment,and the differences were statistically significant(P<0.05).There was no statistical significance in the score of 39 item Parkinson's disease questionnaire(PDQ-39)before treatment between the two groups(P>0.05).The PDQ-39 score of observation group was lower than that of control group after treatment,and the difference was statistically significant(P<0.05).There was no significant difference in serum Hcy and Aβ1-42 between the two groups before treatment(P>0.05).After treatment,the serum Hcy level in the observation group was lower than that in the control group,and the level of Aβ1-42 was higher than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total adverse reaction rate between the two groups(P>0.05).Conclusion Pramipexole+Levodopa and Benserazide Hydrochloride Tablets have significantly better value than Levodopa and Benserazide Hydrochloride Tablets alone in the treatment of Parkinson's disease.At the same time,it can significantly improve patients'motor symptoms,improve their quality of life and Aβ1-42 levels,and reduce Hcy levels,and it is highly safe and worthy of widespread clinical application.